Remote supervision of chemotherapy under the Townsville teleoncology model: what are the perspectives of its users? by Jhaveri, D. et al.
Results: Fourteen patients received abiraterone or enzalutamide prior to
docetaxel and sixteen patients received placebo followed by docetaxel
(control group). We are currently undertaking analysis of response rates,
progression free survival and overall survival following docetaxel and sta-
tistical comparisons between the groups. This analysis will be available for
a poster presentation. Comparison will also be made with historical data of
docetaxel activity in CRPC.
Conclusions: Our analysis is the first to investigate the efficacy of docetaxel
chemotherapy in men with CRPC who have previously received treatment
with enzalutamide or abiraterone. The possibility of cross resistance between
these agents requires careful investigation to determine optimal sequencing
and potential combinations.
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Background: The Townsville Teleoncology model provides videoconferenc-
ing (VC) services to patients in rural and remote areas of North Queensland
to improve access to specialist cancer care. As part of this model, we are now
delivering low risk chemotherapy at three rural sites using VC supervised by
chemotherapy competent nurses in Townsville. The objective is to create a
safe and sustainable model for the provision of chemotherapy to rural
patients. The aim of this study was to explore the experiences of the service
providers to identify the strengths and limitations of this model.
Methods: A cross-sectional descriptive study, using semi-structured inter-
views. Interviews were conducted with twenty participants, including eight
nurses, nine doctors (4 medical oncologists, 4 senior medial officers and one
intern), two rural pharmacists and one administrative officer across all 4
sites. Data was analysed adopting a phenomenological approach.
Results: All participants reported high levels of patient satisfaction due to
cost and travel time savings by providing chemotherapy at their local hos-
pitals. Education was provided to nurses at rural sites to become chemo-
therapy aware. Safe practice was maintained with delivery and handling of
chemotherapy and no adverse events were reported.
Limitations identified were the absence of practical training for rural nurses,
administrative issues with bookings of consultations and lack of a clear
process for the identification and recruitment of suitable patients.
Conclusions: The model has been successful in the safe provision of low risk
chemotherapy to rural cancer patients via VC. Some minor changes are
required to improve and expand the model.
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Background: Human epidermal growth factor receptor 2 over-expression
(HER2+) occurs in 10–15% of breast cancers. Adjuvant trastuzumab with
chemotherapy (ATWC) reduces risk of recurrence and death by 40% and
34% respectively1. T1N0 (≤2cm node-negative) patients were mostly
excluded; hence a lack of information on whether trastuzumab is warranted
in this population.
This study quantifies the real-world ATWC-use in T1N0 HER2+ breast
cancer; and examines if this provides a clinically meaningful benefit, defined
as a 3% improvement in 5-year disease free survival (DFS) and overall
survival (OS). Clinicopathological factors [age; tumour size, oestrogen
receptor (ER) staining, grade, lymphovascular invasion (LVI) and anthracy-
cline treatment] were examined for predictability of benefit.
Methods: All subjects provided written consent for enrolment in a prospec-
tive database of the Australian Capital Territory and South-East New South
Wales Breast Cancer Treatment Group. Planned analysis includes 5-year
DFS and OS estimated by the Kaplan-Meier method. Absolute survival
benefits will be derived by applying the effect of ATWC on DFS and OS in
meta-analysis1 (HR 0.60 and HR 0.66 respectively). A stepwise Cox regres-
sion analysis will examine the effect clinicopathological factors on survival.
Results: One hundred women with T1N0 HER2+ breast cancer diagnosed
between July 2005 – June 2013, mean age 58yo (range 32–84yo), were
identified. They comprised 59% ER+, predominantly higher grade (95%
grade 2–3) and 10% LVI+ cases. All ER+ patients received endocrine
therapy. ATWC was given in 52%. The ATWC-treated compared with
ATWC-untreated patients had similar mean age (56yo versus 60yo) and ER+
rate (54% versus 65%, p = 0.28) as untreated patients. One patient had
disease recurrence (ATWC-treated) and six died (5 ATWC-untreated).
Conclusions: We identified a cohort of T1N0 HER2+ breast cancer who
received ATWC in a real-world modern chemotherapy era. Interim results
suggest a good outcome in these patients. The final survival analysis is
planned with additional data from interstate collaborators.
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Background: Elderly patients with mRCC treated with sunitinib in prospec-
tive trials derived survival benefits comparable to younger patients with
acceptable tolerability1. We compared the usage and outcome of sunitinib
between mRCC patients aged <70 years old and ≥70 years old treated in five
Australian centres.
Methods: mRCC patients from hospitals across Victoria and the Australian
Capital Territory diagnosed between 2006–2012 were studied retrospec-
tively. Patients <70yo and ≥70yo were compared with regards to demo-
graphics, clinicopathologic features, treatment and survival, as estimated by
the Kaplan-Meier method. Median time on first line sunitinib was used as a
surrogate for progression free survival (PFS). Survival differences between
groups were compared using the log-rank test.
Results: The cohort of 212 patients included 50 (24%) ≥70yo there were no
significant differences in baseline characteristics including predominance of
clear cell histology (60%), ECOG <2 (52%) and favourable/intermediate
MSKCC risk (66%), compared with <70yo patients. Elderly patients were
more likely to receive best supportive care only compared with younger
patients (46% versus 16%, p < 0.0001). Of those who received systemic
therapy most received sunitinib (n = 20, 74%). More elderly patients com-
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